CLDI — Calidi Biotherapeutics, Inc.

NYSE · Health Care · Biotechnology · CIK 1855485 ·
Last close
$0.18
Market Cap
$3.42M
52W High
$0.84
52W Low
$0.16
ADV30
7,907,236
Next earnings
Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors. It also offers oncolytic virus platforms, such as NeuroNova and SuperNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 0 -4,187,000 -4,108,000 9,591,000 6,631,000 4,656,000
Dec 2025 0 -4,466,000 -4,056,000 8,857,000 5,600,000 5,098,000
Sep 2025 0 -5,048,000 -5,149,000 14,029,000 10,375,000 6,831,000
Jun 2025 0 -5,664,000 -5,715,000 9,351,000 5,279,000 7,275,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-21,293,000
Investing CF
$-170,000
Financing CF
$17,459,000
CapEx
$-120,000
Dividends Paid
$0
Buybacks
EPS Diluted TTM
$-14.11
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-141,621,000
Inventory
Receivables
$50,000
ST Investments
EBIT TTM
$-19,841,000
Pretax Income TTM
$-20,048,000
Interest Exp TTM
$207,000
Analysts

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 0 -20,190,000 -19,906,000 8,857,000 5,098,000 -21,293,000
Dec 2024 0 -21,595,000 -22,143,000 14,182,000 12,214,000 -19,694,000
Dec 2023 0 -26,107,000 -29,216,000 10,019,000 18,254,000 -26,983,000
Dec 2022 45,000 -23,128,000 -25,427,000 2,597,000 53,037,000 -13,214,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.90

Peers — same industry

TickerNameMarket CapLastDaily %
AIM AIM ImmunoTech Inc. $3.39M $0.23
VIVS VivoSim Labs, INC. $3.73M $1.29
APTOF Aptose Biosciences Inc. $4.29M $1.68
CPMV Mosaic ImmunoEngineering Inc. $5.03M $0.69
SCNI Scinai Immunotherapeutics Ltd. $1.91M $0.48

News headlines (Yahoo Finance, 1h cache)

Calidi Biotherapeutics Announces Online Abstract Acceptances at the 2026 ASCO Annual Meeting
2026-05-26 12:00 · Yahoo
Calidi Biotherapeutics Provides Required NYSE American Disclosure
2026-05-22 22:00 · Yahoo
Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights
2026-05-14 20:10 · Yahoo
Calidi Biotherapeutics Confirms Featured Speaker Presentation Tomorrow at the ASGCT Conference in Boston
2026-05-13 12:00 · Yahoo
Calidi Biotherapeutics Announces Strategic Partnership with TransferAI to Drive Efficiencies in the IND Submission Process for CLD-401 Using Agentic AI
2026-04-29 12:00 · Yahoo
RedChip's Biotech Virtual Investor Conference Replays Now Available
2026-04-21 19:00 · Yahoo
Calidi Biotherapeutics Presents New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026
2026-04-21 12:00 · Yahoo
Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026
2026-04-20 12:00 · Yahoo
Calidi Biotherapeutics Announces Participation in RedChip’s April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms
2026-04-15 12:00 · Yahoo
Calidi Biotherapeutics Announces Speaker Presentation at IOVC Conference in Reykjavík, Iceland on April 28th Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of
2026-04-14 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.